Pages that link to "Q79936448"

The following pages link to Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis (Q79936448):

Displaying 45 items.

• Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration (Q26769021) (← links)
• Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review (Q26995202) (← links)
• Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns (Q30572825) (← links)
• Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature (Q33387149) (← links)
• Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration (Q33956370) (← links)
• Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience (Q34036038) (← links)
• Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations (Q34194003) (← links)
• Oral administration of nano-emulsion curcumin in mice suppresses inflammatory-induced NFκB signaling and macrophage migration. (Q34450324) (← links)
• Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). (Q35990760) (← links)
• Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis. (Q36145205) (← links)
• Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease (Q36209653) (← links)
• Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases (Q36372720) (← links)
• Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis (Q36462243) (← links)
• Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry (Q36584169) (← links)
• Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists (Q37120627) (← links)
• The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis (Q37139401) (← links)
• Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics (Q37148784) (← links)
• Methotrexate for ocular inflammatory diseases (Q37204512) (← links)
• Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types (Q37635204) (← links)
• Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis (Q37745676) (← links)
• Optimizing methotrexate therapy in rheumatoid arthritis: A systematic literature review (Q37858789) (← links)
• Needle-free and microneedle drug delivery in children: A case for disease-modifying antirheumatic drugs (DMARDs) (Q37902280) (← links)
• Methotrexate revisited: considerations for subcutaneous administration in RA. (Q38272682) (← links)
• The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review. (Q38357969) (← links)
• Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics? (Q38758521) (← links)
• Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. (Q38939820) (← links)
• Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. (Q38991972) (← links)
• MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. (Q39062211) (← links)
• A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells (Q39453054) (← links)
• Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats (Q40772231) (← links)
• In-vivo monitoring of anti-folate therapy in arthritic rats using [18F]fluoro-PEG-folate and positron emission tomography (Q41808297) (← links)
• An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis (Q41994612) (← links)
• Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin (Q42414457) (← links)
• Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis (Q49163962) (← links)
• Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism (Q50047899) (← links)
• Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate (Q50794926) (← links)
• Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability. (Q54956831) (← links)
• Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t (Q56966479) (← links)
• How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. (Q64927637) (← links)
• [Methotrexate: advantages of subcutaneous administration] (Q81175622) (← links)
• How to effectively use methotrexate in rheumatoid arthritis? (Q82532347) (← links)
• When should we use parenteral methotrexate? (Q84396532) (← links)
• Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis? (Q87499001) (← links)
• Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial (Q92771579) (← links)
• Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis (Q93147194) (← links)